In the Claims

Please substitute the following claim 1 for the claim 1 now pending in the above-identified application.

Please cancel claims 25-28.

Please add new claims 50-53.

- 1. (Currently Amended) An orally disintegrable tablet which comprises
 - (i) fine granules having an average particle diameter of 400 µm or less, which fine granules comprise a composition coated by an enteric coating layer comprising a first component which is an enteric coating agent and a second component which is a sustained release agent, said composition having 10 weight % or more of an acid-labile physiologically active substance and
 - (ii) a water-soluble sugar alcohol, crystalline cellulose, low-substituted

 hydroxypropyl cellulose or a combination thereof

wherein the water-soluble sugar alcohol is in an amount of 5 to 97 weight % relative to 100 weight % of the orally disintegrable tablet apart from the fine granules;

wherein said tablet having a hardness strength of about 1 to about 20 kg is orally disintegrable;

and wherein the oral disintegration time of said tablet is one minute or less.

- 2. (Original) An orally disintegrable tablet of claim 1, wherein the average particle diameter of the fine granules is 300 to 400 μ m.
- 3. (Original) An orally disintegrable tablet of claim 1, wherein the fine granules further comprise a basic inorganic salt.

Claim 4 (Cancelled)

5. (Original) An orally disintegrable tablet of claim 1, wherein the composition coated by an enteric coating layer is further coated by a coating layer which comprises a water-soluble sugar alcohol.

Claim 6 (Cancelled)

- 7. (Original) An orally disintegrable tablet of claim 1, wherein the particle diameter of the fine granules is practically 425 µm or less.
 - 8. (Cancelled)
- 9. (Original) An orally disintegrable tablet of claim 1, wherein the acid-labile physiologically active substance is a benzimidazole compound or a salt thereof.
 - 10. (Cancelled)
- 11. (Original) An orally disintegrable tablet of claim 3, wherein the basic inorganic salt is a salt of magnesium and/or a salt of calcium.
- 12. (Original) An orally disintegrable tablet of claim 1, wherein the composition comprises a core being coated by a benzimidazole compound and a basic inorganic salt, said core comprising crystalline cellulose and lactose.
- 13. (Original) An orally disintegrable tablet of claim 12, wherein the core comprises

50 weight % or more of lactose.

- 14. (Original) An orally disintegrable tablet of claim 12, wherein the core comprises 40 to 50 weight % of crystalline cellulose and 50 to 60 weight % of lactose.
- 15. (Original) An orally disintegrable tablet of claim 1, wherein the composition comprises 20 weight % or more of an acid-labile physiologically active substance.
- 16. (Original) An orally disintegrable tablet of claim 1, wherein the composition comprises 20 to 50 weight % of an acid-labile physiologically active substance.
- 17. (Original) An orally disintegrable tablet of claim 1, wherein the fine granules are produced by fluidized-bed granulation method.
- 18. (Original) An orally disintegrable tablet of claim 1, wherein the enteric coating layer comprises an aqueous enteric polymer agent.
- 19. (Original) An orally disintegrable tablet of claim 18, wherein the aqueous enteric polymer agent is a methacrylate copolymer.
 - 20. (Cancelled)
- 21. (Previously Presented) An orally disintegrable tablet of claim 1, wherein the sustained-release agent is a methacrylate copolymer.

- 22. (Previously Presented) An orally disintegrable tablet of claim 1, wherein the sustained-release agent is in an amount of 5 to 15 weight % relative to 100 weight % of the aqueous enteric polymer agent.
- 23. (Previously Presented) An orally disintegrable tablet of claim 1, wherein the water-soluble sugar alcohol is erythritol.
- 24. (Previously Presented) An orally disintegrable tablet of claim 1, wherein the water-soluble sugar alcohol is mannitol.

Claims 25-28 (Cancelled)

- 29. (Original) An orally disintegrable tablet of claim 1, which further comprises crospovidone.
 - 30. (Cancelled)
- 31. (Original) An orally disintegrable tablet of claim 1, which comprises no lubricant inside the tablet.

Claims 32-49. (Cancelled)

50. (New) An orally disintegrable tablet of claim 1, wherein an additive selected from U.S. Patent Application Serial No. 10/017,755

crystalline cellulose, low substituted hydroxypropyl cellulose or a combination thereof is further comprised in combination with said water-soluble sugar alcohol.

- 51. (New) An orally disintegrable tablet of claim 50, wherein the crystalline cellulose is in an amount of 3 to 50 weight % relative to 100 weight % of the tablet apart from the fine granule.
- 52. (New) An orally disintegrable tablet of claim 50, wherein the content of hydroxypropoxyl group in the low-substituted hydroxypropyl cellulose is 7.0 to 9.9 weight %.
- 53. (New) An orally disintegrable tablet of claim 50, wherein the content of hydroxypropoxyl group in the low-substituted hydroxypropyl cellulose is 5.0 to 7.0 weight %.